subscribeSubscribe
Spectrum to lay off R&D staff after FDA drug rejection

Spectrum to lay off R&D staff after FDA drug rejection
BIOPHARMADIVE
29 Nov 2022
Share Share
Spectrum implodes after aharsh public slapdown and a CRL from Richard Pazdur

Spectrum implodes after aharsh public slapdown and a CRL from Richard Pazdur
ENDPTS
28 Nov 2022
Share Share
FDA hands Hanmi’s partner, Spectrum, a poziotinib CRL for supplementary data

FDA hands Hanmi’s partner, Spectrum, a poziotinib CRL for supplementary data
KOREABIOMED
25 Nov 2022
Share Share
Spectrum Provides Update on Poziotinib Following FDA Oncologic Advisory Meeting

Spectrum Provides Update on Poziotinib Following FDA Oncologic Advisory Meeting
BUSINESSWIRE
22 Sep 2022
Share Share
FDA staff flag concerns with cancer treatments from Spectrum, Oncopeptides

FDA staff flag concerns with cancer treatments from Spectrum, Oncopeptides
REUTERS
21 Sep 2022
Share Share
Spectrum Announces Data from Presentation for Poziotinib in NSCLC Patients

Spectrum Announces Data from Presentation for Poziotinib in NSCLC Patients
BUSINESSWIRE
10 Sep 2022
Share Share
Spectrum Announces Presentation for Poziotinib in NSCLC Patients

Spectrum Announces Presentation for Poziotinib in NSCLC Patients
BUSINESSWIRE
05 Sep 2022
Share Share
Hanmi to start confirmatory NSCLC trial of poziotinib in Korea

Hanmi to start confirmatory NSCLC trial of poziotinib in Korea
Kim Chan-hyuk KOREABIOMED
17 Aug 2022
Share Share
Spectrum Pharmas Reports Second Quarter 2022 Financial Results

Spectrum Pharmas Reports Second Quarter 2022 Financial Results
BUSINESSWIRE
11 Aug 2022
Share Share
Spectrum Pharma Presents Positive Data for Poziotinib in First-line NSCLC

Spectrum Pharma Presents Positive Data for Poziotinib in First-line NSCLC
BUSINESSWIRE
07 Mar 2022
Share Share